Ippolito J, Hartig J, Bejar K, Nakhoul H, Sehn J, Weimholt C
Mol Cancer Res. 2024; 23(1):59-70.
PMID: 39417716
PMC: 11694069.
DOI: 10.1158/1541-7786.MCR-24-0660.
Hartig J, Bejar K, Young L, Grimsley G, Bethard J, Troyer D
Cancer Res Commun. 2024; 4(11):3036-3048.
PMID: 39347566
PMC: 11600299.
DOI: 10.1158/2767-9764.CRC-24-0152.
Baroni R
Radiol Bras. 2024; 57:e5.
PMID: 39315282
PMC: 11419565.
DOI: 10.1590/0100-3984.2024.57.e5-en.
Chen B, Guo L, Wang L, Wu P, Zheng X, Tan C
Sci Rep. 2024; 14(1):21680.
PMID: 39289451
PMC: 11408614.
DOI: 10.1038/s41598-024-72985-w.
Maes J, Gesquiere S, De Spiegeleer A, Maes A, Van de Wiele C
Int J Mol Sci. 2024; 25(17).
PMID: 39273701
PMC: 11396261.
DOI: 10.3390/ijms25179755.
Salvage therapies for biochemical recurrence after definitive local treatment: a systematic review, meta-analysis, and network meta-analysis.
Matsukawa A, Yanagisawa T, Fazekas T, Miszczyk M, Tsuboi I, Kardoust Parizi M
Prostate Cancer Prostatic Dis. 2024; .
PMID: 39266730
DOI: 10.1038/s41391-024-00890-4.
Whole pelvis vs. hemi pelvis elective nodal radiotherapy in patients with PSMA-positive nodal recurrence after radical prostatectomy - a retrospective multi-institutional propensity score analysis.
Trapp C, Aebersold D, Belka C, Casuscelli J, Emmett L, Eze C
Eur J Nucl Med Mol Imaging. 2024; 51(12):3770-3781.
PMID: 38940843
PMC: 11445306.
DOI: 10.1007/s00259-024-06802-x.
Overview of Radiation Therapy in the Management of Localized and Metastatic Prostate Cancer.
Mattes M
Curr Urol Rep. 2024; 25(8):181-192.
PMID: 38861238
DOI: 10.1007/s11934-024-01217-5.
Development and Validation of a Multimodality Model Based on Whole-Slide Imaging and Biparametric MRI for Predicting Postoperative Biochemical Recurrence in Prostate Cancer.
Hu C, Qiao X, Huang R, Hu C, Bao J, Wang X
Radiol Imaging Cancer. 2024; 6(3):e230143.
PMID: 38758079
PMC: 11148661.
DOI: 10.1148/rycan.230143.
An integrated radiology-pathology machine learning classifier for outcome prediction following radical prostatectomy: Preliminary findings.
Hiremath A, Corredor G, Li L, Leo P, Magi-Galluzzi C, Elliott R
Heliyon. 2024; 10(8):e29602.
PMID: 38665576
PMC: 11044050.
DOI: 10.1016/j.heliyon.2024.e29602.
Patient-centred pathology reporting improves patient experience and understanding of disease in prostate cancer care.
Al Saffar H, Thomson A, Tan J, Wang Q, Birch E, Koschel S
BJUI Compass. 2024; 5(4):497-505.
PMID: 38633832
PMC: 11019249.
DOI: 10.1002/bco2.322.
The Current Therapeutic Landscape for Metastatic Prostate Cancer.
Bernal A, Bechler A, Mohan K, Rizzino A, Mathew G
Pharmaceuticals (Basel). 2024; 17(3).
PMID: 38543137
PMC: 10974045.
DOI: 10.3390/ph17030351.
Stroma-specific gene expression signature identifies prostate cancer subtype with high recurrence risk.
Rasmussen M, Fredsoe J, Salachan P, Blanke M, Larsen S, Ulhoi B
NPJ Precis Oncol. 2024; 8(1):48.
PMID: 38395986
PMC: 10891092.
DOI: 10.1038/s41698-024-00540-x.
Salvage Radiotherapy for Relapsed Prostate Cancer after Radical Prostatectomy Is Associated with Normal Life Expectancy.
Lohm G, Knornschild F, Neumann K, Budach V, Schwartz S, Burock S
Cancers (Basel). 2024; 16(3).
PMID: 38339285
PMC: 10854858.
DOI: 10.3390/cancers16030534.
Prostate Cancer Skeletal Metastasis: A Spontaneous Evolution from Osteolytic to Osteoblastic Morphology without Treatment.
Lawal I, Bilen M, Halkar R, Jani A, Schuster D
World J Nucl Med. 2023; 22(4):316-320.
PMID: 38152102
PMC: 10751110.
DOI: 10.1055/s-0043-1777697.
Association between copy number alterations estimated using low-pass whole genome sequencing of formalin-fixed paraffin-embedded prostate tumor tissue and cancer-specific clinical parameters.
Salachan P, Ulhoi B, Borre M, Sorensen K
Sci Rep. 2023; 13(1):22445.
PMID: 38105358
PMC: 10725894.
DOI: 10.1038/s41598-023-49811-w.
Predicting F-DCFPyL-PET/CT Scan Positivity in Prostate Cancer Patients with Biochemical Recurrence.
Lee K, Mena E, Shih J, Lindenberg L, Wood B, Pinto P
Acad Radiol. 2023; 31(4):1419-1428.
PMID: 37775447
PMC: 10965502.
DOI: 10.1016/j.acra.2023.09.002.
Prostate-specific membrane antigen radioguided surgery with negative histopathology: an in-depth analysis.
Koehler D, Trappe S, Shenas F, Karimzadeh A, Apostolova I, Klutmann S
Eur J Nucl Med Mol Imaging. 2023; 51(2):548-557.
PMID: 37750908
PMC: 10774205.
DOI: 10.1007/s00259-023-06442-7.
Stereotactic body radiation therapy after radical prostatectomy: current status and future directions.
Le Guevelou J, Magne N, Counago F, Magsanoc J, Vermeille M, de Crevoisier R
World J Urol. 2023; 41(11):3333-3344.
PMID: 37725131
DOI: 10.1007/s00345-023-04605-7.
Focal ablation therapy presents promising results for selectively localized prostate cancer patients.
Feng D, Li D, Xiao Y, Wu R, Wang J, Zhang C
Chin J Cancer Res. 2023; 35(4):424-430.
PMID: 37691892
PMC: 10485919.
DOI: 10.21147/j.issn.1000-9604.2023.04.08.